CN Patent

CN108992454B — 一种治疗皮肤炎症性疾病的复方药物组合物

Assigned to Hefei Amvite Pharmaceutical Co ltd · Expires 2020-06-02 · 6y expired

What this patent protects

本发明涉及药物技术领域，具体涉及一种治疗皮肤炎症性疾病的复方药物组合物，其特征是，本发明复方药物的活性成分由托法替尼和克立硼罗组成，该组合物具有更强的治疗效果和更低的使用剂量，具有显著的协同治疗效果，本发明的药物组合物可用于治疗皮肤炎症性疾病。

USPTO Abstract

本发明涉及药物技术领域，具体涉及一种治疗皮肤炎症性疾病的复方药物组合物，其特征是，本发明复方药物的活性成分由托法替尼和克立硼罗组成，该组合物具有更强的治疗效果和更低的使用剂量，具有显著的协同治疗效果，本发明的药物组合物可用于治疗皮肤炎症性疾病。

Drugs covered by this patent

Patent Metadata

Patent number
CN108992454B
Jurisdiction
CN
Classification
—
Expires
2020-06-02
Drug substance claim
No
Drug product claim
No
Assignee
Hefei Amvite Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.